ThisDay (4 October 2026) reports that an expanded partnership between the National Health Insurance Authority (NHIA) and Roche is meant to reduce the cost of selected cancer medicines for eligible insured patients. It says the patient's direct burden falls by 80%.
The reported split is Roche 50%, NHIA 30% and the patient 20%. ThisDay says NHIA has also added radiotherapy support 'ranging from up to N400,000 to full coverage' and is keeping diagnostics benefits such as mammography, CT and MRI scans, bone scans and laboratory tests.
Punch reports that the NHIA has expanded insurance support to shield eligible patients from 80% of medicine cost.
The same 50/30/20 arrangement was reported at hospitals such as JUTH, ATBUTH and UITH in earlier coverage, so it is unclear how much of the October 2026 'expansion' is new.
What the sources say
- ThisDay: The NHIA-Roche scheme leaves insured, eligible patients paying 20% of selected cancer drugs. NHIA has added radiotherapy support of up to N400,000 to full coverage and keeps diagnostics benefits.
- Punch: It reports that the NHIA has expanded insurance support to cut cancer treatment costs and shield eligible patients from 80% of medicine cost.
- Leadership: Reports the same 50/30/20 split and radiotherapy support from N400,000 to full coverage. It says enrolment passed 23 million and quotes NHIA's Kelechi Ohiri on whether coverage turns into access and financial protection.
- Premium Times: In an undated report likely from early 2025, Ohiri told NAN that NHIA gives a 50% subsidy on radiotherapy capped at N400,000. He also said chemotherapy drugs are partly or fully covered through cost-sharing and that NHIA works with Roche and Pfizer.
- BusinessDay: A JUTH official said the scheme is only for NHIA-registered patients and that NHIA covers 30% 'once a patient is selected', which implies a selection step.
- Leadership: At ATBUTH, non-enrolled patients still get Roche's 50% but pay the other 50%. Newly enrolled patients reportedly wait two months before they can use the benefit.
- Leadership: A UITH surgeon called the initiative commendable but said 20% is still high and asked NHIA to cut it to 10% or 5%.
- Daily Trust: An opinion/feature piece calls the Roche scheme welcome but 'limited in scope and reach'. It says a N400,000 radiotherapy cap is small against a N2 million bill and mentions an NHIA plan for Catastrophic Health Insurance.
- Daily Trust: A patient said NHIA covered 50% of her Herceptin and Perjeta drugs costing over N900,000. A Cancer Health Fund committee chair said manufacturer participation cut a combined dose from N1.5m to N600,000.
Where the sources agree
- Every source that gives the drug cost structure reports the same split: Roche 50%, NHIA 30%, patient 20%.
- ThisDay and Leadership both report radiotherapy support from up to N400,000 to full coverage.
- ThisDay, Leadership and Premium Times give consistent lists of covered diagnostics, including mammography, CT and MRI scans.
- The scheme applies to NHIA-enrolled patients and to 'selected' medicines, not to all cancer drugs.
Where they differ
How radiotherapy support is described
- ThisDay: Reports radiotherapy support 'ranging from up to N400,000 to full coverage' for eligible patients, without saying who gets full coverage.
- Premium Times: Quotes Ohiri describing a 50% subsidy on radiotherapy capped at N400,000. This may be an earlier version, but no source confirms that.
Who qualifies and what non-enrolled patients get
- ThisDay: Refers to 'eligible insured patients' without setting out the criteria.
- BusinessDay: A JUTH official said NHIA's 30% applies 'once a patient is selected', suggesting a selection step.
- Leadership: Reports a two-month wait for new enrollees. Non-enrolled patients get only Roche's 50% and pay the rest.
Whether the scheme goes far enough
- ThisDay: Presents the scheme as removing 80% of medicine cost from the patient's direct burden.
- Daily Trust: Calls it welcome but limited in scope and reach, and says the radiotherapy cap is small against a N2 million bill.
- Leadership: A UITH surgeon said the 20% patient share is still high and should be 10% or 5%.
What the authorities say
NHIA Director-General Kelechi Ohiri, quoted by Leadership and referred to by ThisDay, says the Authority is focused on implementation and on whether coverage translates into access, financial protection and a better healthcare experience. He told NAN earlier that NHIA is working with Roche and Pfizer and aims to increase accredited radiotherapy centres. Daily Trust reports an NHIA policy plan for Catastrophic Health Insurance covering cancers, sickle cell disease and end-stage renal disease; this is a plan, not an implemented programme. We found no statement from the Federal Ministry of Health, NAFDAC or Roche Nigeria on the October 2026 reports, though the search was limited.
What this means for you
An insured, eligible patient on a selected Roche cancer drug would pay 20% of its cost. As illustrative arithmetic only, a N900,000 course would leave N180,000 to pay. No source gives a price for a specific drug.
The 80% figure is the press's calculation, not a quoted NHIA figure. It covers only 'selected' medicines, so many cancer drugs may not qualify.
Enrolment matters. Non-enrolled patients reportedly get only Roche's 50%, and new enrollees may wait two months.
Radiotherapy help may be capped at N400,000 for some patients, which could leave a large gap against a bill like the N2 million Daily Trust cites. The 'full coverage' rules are not explained.
Diagnostics such as mammography, CT and MRI scans, bone scans and lab tests are reported as covered for NHIA enrollees.
What you can do
- If you are not enrolled with NHIA, ask about enrolment and any waiting period before treatment is planned. Reports mention a two-month wait for new enrollees.
- Before starting treatment, ask the hospital's NHIA desk in writing whether your specific drug is on the 'selected' list. Ask what you will pay and whether you need to be selected.
- Ask for the full cost breakdown, including radiotherapy, and whether the N400,000 cap or full coverage applies to you.
- Keep copies of enrolment details, prescriptions, quotes and receipts, and ask your accredited facility to confirm cover in writing.
- Treat any claim of 80% off with care until your hospital or NHIA confirms it for your case. Do not pay anyone outside official hospital or NHIA channels to 'secure' the benefit.
ConsumersNG is a consumer research platform, not a financial adviser, lawyer or medical professional. These steps are general information to help you ask the right questions. Before making decisions about your money, health or legal rights, check with the relevant regulator or a qualified professional. Read our full Disclaimer.
Still unclear
- Which drugs and which hospitals are covered? No NHIA or Roche list was found; Herceptin and Perjeta appear only in a patient's account and a Cancer Health Fund official's remark.
- What exactly is new in October 2026? The 50/30/20 scheme was reported at JUTH, ATBUTH and UITH in mid-2025, so this may be an extension to more sites or a restatement.
- Is radiotherapy support 'up to N400,000 to full coverage' or a 50% subsidy capped at N400,000? Who gets full coverage?
- What are the eligibility and selection criteria, and how long is the waiting period?
- What do the Punch report and any statement from NHIA or Roche Nigeria add?
- The 51,000 enrolment figure for Anambra, Ebonyi, Gombe and Kwara refers to 'the intervention', and it is not clear whether this is the cancer scheme.
ConsumersNG's view
Many outlets report the same 50/30/20 split, so it looks solid: Roche pays 50%, NHIA 30% and the patient 20%. The claim that drugs are 80% cheaper needs more care. It was worked out in press reports, covers only some drugs and eligible insured patients, and the full price has not been made public. What matters to you is the bill for your own drug.
Cheaper drugs help, and NHIA is right to focus on access and on protecting patients from huge bills. But Daily Trust and a surgeon at the University of Ilorin Teaching Hospital (UITH) point to real gaps. Paying 20% can still be heavy when treatment costs hundreds of thousands of naira, and the cap on radiotherapy may not cover large bills. We still do not know how many patients get full cover, or which drugs are on the list.
Watch out for unclear rules on who qualifies, waiting periods, and the gap between best-case headline figures and what you actually pay. Get written confirmation from the hospital and NHIA before treatment starts. Do not pay anyone who offers to speed things up for a fee. We want NHIA and Roche Nigeria to publish the drug list, the hospitals taking part and the rules on who qualifies, in plain language.
This is ConsumersNG's opinion based on the sources above. It is not financial, legal or investment advice. Please speak to a qualified adviser before making decisions.
Sources & references
- SupportsThisDay NHIA Urges Early Detection as FG Steps Up Cancer Response
- SupportsPunch NHIA expands cover to cut cancer treatment costs
- SupportsLeadership Health Insurance Enrolment Hits 23m As NHIA Widens Cancer, HIV, TB Cover
- ContextThisDay NHIA Enrolment Hits 23m, Expands Disease Cover
- ContextPremium Times NHIA introduces N400,000 cancer treatment subsidy to ease patient burden
- ContextBusinessDay JUTH partners Roche pharmaceutical to provide subsidised cancer medication
- ContextLeadership NHIA, Roche Introduce Subsidised Cancer Care At ATBUTH
- CountersLeadership NHIA Partners Roche On Cancer Patients' Treatment
- CountersDaily Trust The Heavy Price of Hope
- ContextDaily Trust Cancer Health Fund: Patients, survivors lament challenges
Researched with AI assistance and reviewed by a ConsumersNG editor. How we research.